By the year 2036, hepatitis C will be a rare disease affecting just one in every 1,500 people in the U.S., according to a new predictive model developed at the University of Pittsburgh Graduate School of Public Health. The analysts say the number of cases will plummet courtesy of effective new drugs, including Gilead Sciences’ Sovaldi, and new screening guidelines. Currently, about one in every 100 Americans has chronic hepatitis C, a contagious liver disease, ranging in severity from a mild illness lasting just a few weeks to a chronic, lifelong sickness requiring, in some cases, a liver transplant.
Hey, check out all the research scientist jobs. Post your resume today!
